Veradermics Incorporated (MANE) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Veradermics Incorporated (NYSE: MANE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $129.53 (-7.27% 1D, market cap $5.84B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, MANE ranks #203 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MANE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.9%. By comparison, GRFS (Grifols S.A.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.57B) and MIRM (Mirum Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -3.9%, cap $5.52B). Among the 5-stock peer group, MANE leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).
Per MANE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001827635), Veradermics Incorporated generated $202.6M in revenue (+170.2% YoY), -$70.0M in net income, and -$71.6M in free cash flow against $152.6M in total assets and $4.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
Even with a 55/100 (D+) score, MANE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($117.06) or 200D SMA ($94.61) invalidates the momentum regime and cuts Target Base ($127.78) toward Bear Floor ($99.67).
Veradermics Incorporated (MANE) dropped -7.27% to $129.53, trading at 85% of its 52-week range ($32 – $146.58). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Veradermics' shares are up nearly 270% since its IPO earlier this year.
B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +170.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MANE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MANE. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Veradermics Incorporated (MANE) ranks #203 by composite RQD confidence (55/100, grade D+) and #146 by equity capitalization ($5.84B). Within this direct 5-issuer industry benchmark cohort, MANE leads on earnings valuation at N/A trailing P/E, while MIRM leads on capital efficiency and profitability with -3.9% ROIC and — gross margin. MANE currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MANE
ACTIVE
Veradermics Incorporated | D+ | 55/100 | — | — | -11.9% | -7.27% | $5.84B | Benchmark Subject |
| GRFS Grifols S.A. | D+ | 54/100 | — | — | — | +5.06% | $5.57B | /grfs-vs-mane → |
| MIRM Mirum Pharmaceuticals Inc. | D | 51/100 | — | — | -3.9% | +0.87% | $5.52B | /mirm-vs-mane → |
| BLTE Belite Bio Inc | D- | 36/100 | — | — | -15.9% | -0.69% | $6.23B | /blte-vs-mane → |
| COGT Cogent Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -4.16% | $5.38B | /cogt-vs-mane → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Veradermics Incorporated (MANE) reported GAAP revenue of $202.6M (+170.2% vs. FY2024 revenue of $75.0M ) , GAAP net income of -$70.0M, operating cash flow of -$71.6M, and free cash flow of -$71.6M (-202.4% YoY). On the balance sheet, MANE closed FY2025 with $152.6M in total assets against $4.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $202.6M | -$70.0M | -$71.6M | -$71.6M | $152.6M | $4.1M |
| FY2024 (FY) | 2024-12-31 | $75.0M | -$26.5M | -$23.7M | -$23.7M | $55.5M | $2.1M |
As of 2026-11-03, Veradermics Incorporated (NYSE: MANE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $129.53 (-7.27% 1D, market cap $5.84B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, MANE ranks #203 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MANE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.9%. By comparison, GRFS (Grifols S.A.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.57B) and MIRM (Mirum Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -3.9%, cap $5.52B). Among the 5-stock peer group, MANE leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).
Per MANE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001827635), Veradermics Incorporated generated $202.6M in revenue (+170.2% YoY), -$70.0M in net income, and -$71.6M in free cash flow against $152.6M in total assets and $4.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
MANE last traded at $129.53 (-7.27% on volume of 636,757 shares), positioning the stock +10.65% above its 50-day simple moving average ($117.06) and +36.91% above its 200-day simple moving average ($94.61). Across its 52-week range of $32.00 to $146.58, MANE sits at the 85.1% percentile with a 14-day RSI of 60.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($113.34 to $145.72).
Veradermics Incorporated (MANE) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $129.53 (-7.27% 1D, market capitalization $5.84B).
Veradermics Incorporated (MANE) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $6.0B. Per the financials, reported revenue for FY 2025 and FY 2024 is — in both periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Veradermics Incorporated (MANE) reported $202.6M in annual revenue (up from $75.0M in FY2024, +170.2% YoY) and -$70.0M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($75.0M revenue, -$26.5M net income) through FY2025, MANE scaled operating cash flow to -$71.6M and free cash flow to -$71.6M, backed by $152.6M in total assets against $4.1M in total debt.
— The Butterfly Supply-Chain Graph lists supply_chain as NONE, with no upstream or downstream links, no sector correlations, and no bottlenecks identified in the source data.
Real-time company headlines, analyst actions, and sector developments for Veradermics Incorporated (MANE) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Veradermics Incorporated (MANE) market action, institutional positioning, and fundamental catalysts.
Long MANE at $139.69 targeting $184.39. Institutional accumulation and options positioning score 18 of 20 in the RQD rating, the strongest pillar in the set.. Institutional whale score is 18/20 and the risk/reward vs. the $32.00 52-week low is skewed heavily in favor of bulls.
@TapeReader_Pro Agree on the RQD 55/100 quality, though with 1.07 beta I'm scaling in with half-size at $139.69 and keeping dry powder in case we test $129.91.
I respect the product at Veradermics Incorporated, but the stock at $139.69 is a different story. Negative ROIC of -11.9% and FCF yield of -1.19% drive the weakest pillar at 7 of 20 in the RQD rating.. FCF yield is -1.19% and RQD sits at 55/100 (D+) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: